Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
- Conditions
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Favrille
- Target Recruit Count
- 480
- Registration Number
- NCT00324831
- Locations
- 🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
- Conditions
- Interventions
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 150
- Registration Number
- NCT00324467
- Locations
- 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada
Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2012-07-03
- Lead Sponsor
- Steven E. Coutre
- Target Recruit Count
- 9
- Registration Number
- NCT00313079
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Clare Twist
- Target Recruit Count
- 4
- Registration Number
- NCT00313053
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00299182
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2020-09-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT00290433
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
- Conditions
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 67
- Registration Number
- NCT00290498
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years
- First Posted Date
- 2006-02-02
- Last Posted Date
- 2009-02-12
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 39
- Registration Number
- NCT00285389
- Locations
- 🇫🇷
Regional university hospital, Rennes, France
🇫🇷REgional Hospital, Tours, France
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma
- Conditions
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 65
- Registration Number
- NCT00284271
- Locations
- 🇩🇪
University of Cologne, Cologne, Germany
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 100
- Registration Number
- NCT00274924
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.